Ibex® Design ADC, DNA-to-IND Program

Bring your Antibody-Drug Conjugate vision to life and embark on a seamless journey from bench to clinic with Ibex® Design ADC.

Relying on Lonza's established expertise, this integrated program spans from Mammalian expression through Bioconjugation up to Drug Product development and manufacturing.

Talk to our experts

15 months* from DNA to IND/IMPD

8 months from DNA to tox Drug Substance

10 months from DNA to tox Drug Product

Tailorable technical scope and timelines when necessary to meet your development needs

Your ADC journey starts here

Ibex® Design ADC is a comprehensive program integrating speed, quality and efficiency to facilitate your CMC path to IND in just 15 months.

This unique offering provides an end-to-end supply solution with reduced complexity by combining Lonza's unparalleled mammalian & bioconjugate expertise, refined over decades, with our advanced highly potent fill & finish expertise.

Unlock the full potential of your ADC journey by harnessing the benefits of Lonza's integrated network, helping mitigate development risks for your cytotoxic bioconjugates.

* Estimated timelines. For antibodies, from DNA transfection to delivery of IND-enabling CMC modules. Subject to terms and conditions.

Shaped around you

Our standard Ibex® Design ADC timeline is streamlined through a platform approach across drug substance and drug product activities. This involves combining our pre-established analytical platform with bespoke methods designed for your specific product. The overall program timeline is defined by specific entry criteria, primarily focusing on mAb properties, chemical conjugation steps, and concentration ranges.

Additionally, Lonza can offer a higher level of flexibility on your journey to IND, by shaping our process around your molecule's profile and technical requirements. Our program scope and timeline can be tailored to your specific needs.